Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gross Profit (2020 - 2025)

Historic Gross Profit for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $139000.0.

  • Insight Molecular Diagnostics' Gross Profit rose 17800.0% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 850357.14%. This contributed to the annual value of $740000.0 for FY2024, which is 7917.68% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Gross Profit stood at $139000.0, which was up 17800.0% from $350000.0 recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Gross Profit high stood at $2.6 million for Q4 2021, and its period low was -$866000.0 during Q3 2021.
  • For the 5-year period, Insight Molecular Diagnostics' Gross Profit averaged around $188894.7, with its median value being $50000.0 (2024).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Gross Profit plummeted by 178260.87% in 2021, and later soared by 284444.44% in 2025.
  • Insight Molecular Diagnostics' Gross Profit (Quarter) stood at $2.6 million in 2021, then plummeted by 101.04% to -$27000.0 in 2022, then plummeted by 333.33% to -$117000.0 in 2023, then skyrocketed by 608.55% to $595000.0 in 2024, then tumbled by 76.64% to $139000.0 in 2025.
  • Its Gross Profit stands at $139000.0 for Q3 2025, versus $350000.0 for Q2 2025 and $1.3 million for Q1 2025.